NASDAQ:ADVM
ADVM Stock News
$8.93
-0.240 (-2.62%)
At Close: May 14, 2024
Glass Lewis Joins ISS In Recommending Adverum Shareholders Vote for All Three Independent Sonic Director Nominees
09:48am, Thursday, 06'th May 2021
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
ADVM Stock: From $3.90 To Over $4.15 Pre-Market Explanation
05:37am, Monday, 03'rd May 2021
The stock price of Adverum Biotechnologies Inc (NASDAQ: ADVM) increased by over 6% pre-market. This is why it happened.
-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose --
Why Adverum Biotechnologies Stock Is Plummeting Today
03:54pm, Thursday, 29'th Apr 2021
Adverum Biotechnologies (NASDAQ: ADVM) shares are trading lower after the company announced a Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-0
The Sonic Fund II, L.P. Comments on Adverum Biotechnologies Update Regarding INFINITY Phase 2 Trial of ADVM-022
02:58pm, Thursday, 29'th Apr 2021
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
Why Adverum Biotechnologies Stock Is Imploding Today
11:48am, Thursday, 29'th Apr 2021
Investors are running for the hills following the company's latest clinical update.
ADVM Stock: From $10.16 To $4.70 Pre-Market Explanation
08:25am, Thursday, 29'th Apr 2021
The stock price of Adverum Biotechnologies Inc (NASDAQ: ADVM) fell from $10.16 to $4.70 pre-market. This is why it happened.
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
04:01pm, Wednesday, 28'th Apr 2021
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant
The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc.
05:00pm, Thursday, 22'nd Apr 2021
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum's Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
08:00am, Wednesday, 21'st Apr 2021
Sonic's Nominees Lack Experience and Qualifications to Advance Adverum's Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
08:05am, Friday, 16'th Apr 2021
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM),
HONOLULU, April 8, 2021 /PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (t
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
05:10pm, Wednesday, 17'th Mar 2021
Responds to Intent to Nominate Directors from Sonic Fund
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
09:09am, Friday, 05'th Mar 2021
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
